Education
About Us
Working with TipRanks
Follow Us
Hikma Pharmaceuticals PLC (GB:HIK)
LSE:HIK
Total Valuation
Hikma Pharmaceuticals has a market cap or net worth of £3.06B. The enterprise value is 5.24B.
Market Cap£3.06B
Enterprise Value5.24B
Share Statistics
Hikma Pharmaceuticals has 234,632,190 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding234,632,190
Owned by Insiders11.45%
Owned by Institutions―
Financial Efficiency
Hikma Pharmaceuticals’s return on equity (ROE) is 0.16 and return on invested capital (ROIC) is 11.53%.
Return on Equity (ROE)0.16
Return on Assets (ROA)0.07
Return on Invested Capital (ROIC)11.53%
Return on Capital Employed (ROCE)0.15
Revenue Per Employee359.92K
Profits Per Employee43.20K
Employee Count9,500
Asset Turnover0.60
Inventory Turnover1.85
Valuation Ratios
The current PE Ratio of Hikma Pharmaceuticals is 9.5. Hikma Pharmaceuticals’s PEG ratio is 0.72.
PE Ratio9.5
PS Ratio1.35
PB Ratio1.77
Price to Fair Value1.77
Price to FCF27.81
Price to Operating Cash Flow10.00
PEG Ratio0.72
Income Statement
In the last 12 months, Hikma Pharmaceuticals had revenue of 3.42B and earned 410.43M in profits. Earnings per share was 1.86.
Revenue3.42B
Gross Profit1.37B
Operating Income637.09M
Pretax Income529.89M
Net Income410.43M
EBITDA853.54M
Earnings Per Share (EPS)1.86
Cash Flow
In the last 12 months, operating cash flow was 389.94M and capital expenditures -195.38M, giving a free cash flow of 194.56M billion.
Operating Cash Flow389.94M
Free Cash Flow194.56M
Free Cash Flow per Share0.83
Dividends & Yields
Hikma Pharmaceuticals pays an annual dividend of 26.556p, resulting in a dividend yield of 4.16%
Dividend Per Share26.556p
Dividend Yield4.16%
Payout Ratio46.44%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.86
52-Week Price Change-37.61%
50-Day Moving Average1.55K
200-Day Moving Average1.75K
Relative Strength Index (RSI)26.02
Average Volume (3m)631.74K
Important Dates
Hikma Pharmaceuticals upcoming earnings date is Aug 6, 2026, TBA (Confirmed).
Last Earnings DateFeb 26, 2026
Next Earnings DateAug 6, 2026
Ex-Dividend Date―
Financial Position
Hikma Pharmaceuticals as a current ratio of 1.82, with Debt / Equity ratio of 63.59%
Current Ratio1.82
Quick Ratio1.06
Debt to Market Cap0.35
Net Debt to EBITDA1.55
Interest Coverage Ratio5.89
Taxes
In the past 12 months, Hikma Pharmaceuticals has paid 114.35M in taxes.
Income Tax114.35M
Effective Tax Rate0.22
Enterprise Valuation
Hikma Pharmaceuticals EV to EBITDA ratio is 6.94, with an EV/FCF ratio of 35.80.
EV to Sales1.73
EV to EBITDA6.94
EV to Free Cash Flow35.80
EV to Operating Cash Flow16.16
Balance Sheet
Hikma Pharmaceuticals has £354.13M in cash and marketable securities with £1.65B in debt, giving a net cash position of -£1.30B billion.
Cash & Marketable Securities£354.13M
Total Debt£1.65B
Net Cash-£1.30B
Net Cash Per Share-£5.52
Tangible Book Value Per Share£6.51
Margins
Gross margin is 41.35%, with operating margin of 18.63%, and net profit margin of 12.00%.
Gross Margin41.35%
Operating Margin18.63%
Pretax Margin15.50%
Net Profit Margin12.00%
EBITDA Margin24.96%
EBIT Margin18.63%
Analyst Forecast
The average price target for Hikma Pharmaceuticals is £2,350.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target£2,350.00
Price Target Upside51.22% Upside
Analyst ConsensusModerate Buy
Analyst Count3
Revenue Growth Forecast3.73%
EPS Growth Forecast27.13%